CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 92 enrolled
Drug / intervention
senofilcon A TEST Lens +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03475875
NCT03475875Phase 3Completed
CompareCT.gov

Contact Lenses With New UV-blocker Manufactured With Different Techniques

Johnson & Johnson Vision Care, Inc.·interventional·Posted Mar 23, 2018·Updated Jun 4, 2019

In Brief

A Phase 3 clinical trial evaluating senofilcon A TEST Lens and senofilcon A CONTROL Lens for Correction of Refraction Error and Attenuation of Bright Light. Completed, enrolled 92 participants across 5 sites.

Detailed Summary

This study is a randomized, 4-visit, double-masked, 2x3 bilateral crossover, dispensing trial. The study lenses will be worn as daily wear (DW) for a period of two weeks each with one of the study lenses being worn twice. Each study lens is expected to be worn at least five (5) days per week for at least six (6) hours per day worn. There will be no washout period between study lenses.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCorrection of Refraction Error, Attenuation of Bright Light
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedMar 23, 2018
Enrollment StartFeb 19, 2018
Primary CompletionApr 18, 2018
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 8.3 years ago

Interventions

senofilcon A TEST Lensdevice

senofilcon A with new UV blocker investigational process

senofilcon A CONTROL Lensdevice

senofilcon A with new UV blocker standard process